

AD _____

AWARD NUMBER DAMD17-98-1-8163

TITLE: ROLE OF STAT-3 IN ER- BREAST TUMORS

PRINCIPAL INVESTIGATOR: Premkumar Reddy, Ph.D.

CONTRACTING ORGANIZATION: Temple University School of Medicine
Philadelphia, PA 19140-5196

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 3

20010110 039

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>	2. REPORT DATE August 1999	3. REPORT TYPE AND DATES COVERED Annual (27 Jul 98 - 26 Jul 99)	
4. TITLE AND SUBTITLE Role of Stat-3 in ER- Breast Tumors		5. FUNDING NUMBERS DAMD17-98-1-8163	
6. AUTHOR(S) Premkumar Reddy, Ph.D.		8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Temple University School of Medicine Philadelphia, PA 19140-5196		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		11. SUPPLEMENTARY NOTES	
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE	
13. ABSTRACT <i>(Maximum 200 words)</i> The hypothesis to be tested in this application is whether <i>c-myb</i> and <i>A-myb</i> genes regulate ductal cell proliferation and whether abnormalities in the expression of these genes results in breast cancer. During the first year of this study, we constructed targeting vectors that can be used for the deletion of exons 6 and 9 of mouse <i>A-myb</i> and <i>c-myb</i> genes. These vectors were transfected into embryonic stem cells and G418 resistant clones were screened for homologous recombination. Following selection, the cell lines were subjected to transient Cre expression and selection for ganciclovir-resistant clones. The ES cell clones that have undergone homologous recombination with our targeting vectors were injected into blastocysts to generate chimeric mice. To validate the results obtained from the mouse models in the human system, we have conducted parallel studies with human breast tumor cell lines. Analysis of human breast tumor cell lines showed that <i>c-myb</i> is expressed in a majority of ER+ human breast carcinomas, while <i>A-myb</i> expression is seen predominantly in ER- cell lines. Our results also shows that blockage of the biochemical function of <i>c-myb</i> results in a complete block to ER+ breast tumor cell proliferation.			
14. SUBJECT TERMS Breast Cancer		15. NUMBER OF PAGES 8	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


✓ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



PI - Signature

Date

TABLE OF CONTENTS

	<u>Page Number</u>
Front Cover	1
Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5-6
Progress Report	6-8

A. INTRODUCTION

The *myb* gene family currently consists of three members, named A,B and *c-myb*, all of which encode nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription. Of these, *c-myb* has been studied extensively in cell culture systems of differentiation and transformation and during mouse development. These studies have provided evidence for the crucial function of the *c-myb* gene in the development, proliferation and oncogenesis of the hematopoietic system. A series of recent experiments have implicated a role for this gene family in breast development and breast cancer. The first evidence that implicated a role for *c-myb* in breast tumors came from the observation that this gene is highly expressed in all estrogen receptor positive (ER+) breast tumors. Our *in situ* hybridization studies also show that this gene is highly expressed in proliferating epithelial cells of the ductal epithelium, in virgin as well as pregnant mice, suggesting that this gene, like in the hematopoietic cell system, might play a critical role in the proliferation of these cells. Our *in situ* hybridization studies also show that *A-myb* is not expressed, or is expressed at very low levels, in ductal cells derived from virgin mice. These levels, however, increase dramatically during the cell proliferation that accompanies pregnancy, resulting in ductal branching and alveolar development. Since this phase of ductal branching is mainly induced by the combined action of estrogen and progesterone, these results suggest that *A-myb* might play an important role in this phase of ductal cell proliferation and morphogenesis into alveolar structures. This view was further supported by our studies where we developed *A-myb* null mutant mice, which were unable to produce milk and showed defects in mammary tissue proliferation following pregnancy. The loss of *A-myb* expression seems to result in a loss or diminution of progesterone-induced proliferative events associated with the pregnancy-induced morphogenesis of breast tissue.

Based on these studies, we hypothesized that *c-myb* and *A-myb* genes play a pivotal role in the proliferation of breast epithelial cells in the adult mice. It is our hypothesis that proliferative events associated with ductal cell proliferation of virgin mice is mediated by *c-myb* and that proliferative events associated with ductal branching and alveolar development that occur following pregnancy are mediated by the combined action of *c-myb* and *A-myb*. It is also our contention that proper down regulation of *A-myb* and *c-myb* are essential for apoptotic events associated with involution. Events that lead to deregulation of expression of *c-myb* and *A-myb* might represent a point at which the onset of neoplasia, which, in combination with other mutations and deletions in oncogenes and growth suppressor genes, results in a metastatic disease. *A-myb* null mutant mice have been extremely useful to our understanding of the role of *A-myb* in mammary gland development. Unfortunately, however, *c-myb* null mutant mice have not been very useful to study the role of this gene in mammary gland development since these

mice die in utero due to failure of fetal hepatic hematopoiesis. To address the role of *c-myb* in mammary development, we proposed to develop *c-myb* mutant mice where the expression of this gene is interrupted specifically in the mammary gland using the Cre-*lox* system.

Task 1: Months 1-12: During this period we proposed to construct targeting vectors that can be used for the deletion of exons 6 and 9 of mouse *c-myb* genes. These vectors were to be transfected into embryonic stem cells and G418 resistant clones were to be screened for homologous recombination. Following the selection of the clones, the cell lines were to be subjected to transient Cre expression and selection for ganciclovir-resistant clones.

B. PROGRESS REPORT

To generate breast-specific *c-myb* null genotype in mice, we have isolated a Bam HI genomic clone of *c-myb* encoding exons 2 through 8, which was used to produce a gene targeting vector (Fig. 1). A 0.9 kb fragment containing exon 6 was generated by PCR amplification and cloned into the BamHI site of the *pflox* vector. The flanking 6.0 kbp fragment on the 5' end containing exons 2-5 was generated by a combination of PCR and restriction enzyme digestion and cloned into the Sall site. Similarly, the flanking 2.5 kb fragment on the 3' end containing exons 7-8 was generated by a combination of PCR and restriction enzyme digestion and cloned into the XhoI site. Following the construction of the targeting vector, the entire clone was sequenced to ascertain that PCR technique did not produce any mutations or deletions.

The targeting construct, linearized by NotI digestion, was introduced into ES cells via electroporation. ES cells were plated on gelatin coated culture plates and selected for 10 days with medium containing 150 µg/ml of active G418. This procedure yielded approximately 600 clones. Genomic DNA from these ES clones was digested with StuI and homologous recombinants identified by Southern blotting using *c-myb* specific probe downstream of exon 9. Homologous recombinants (Fig. 2) revealed two bands: 11.5 kb (wt) and 12.6 kb (recombinant). In order to verify that the recombinants retained all the three *loxP* sites, DNA digested with EcoRI was analyzed by Southern blotting using *loxP* specific probe. All the positive recombinants revealed three bands of sizes 0.3 kb, 1.7 kb and 2.1 kb indicating the presence of 5' *loxP*, internal *loxP* and 3' *loxP* sites respectively.

To produce ES cell subclones that contained the Type I (systemic) and Type II (conditional) *c-myb* mutations, ES clones were subjected to transient Cre expression by electroporation of supercoiled pPGK-Cre-bpA and subsequent selection in the presence of ganciclovir. Subclones resistant to ganciclovir were isolated and analyzed by genomic Southern blotting. Using the genomic probe on DNA digested with BamHI, Type II deletions were verified by identifying a band of 6.0 kbp. Type I deletions would reveal a band





Fig 1. Mouse *c-myb* genomic structure and targeting vector production. (A) Restriction map of the mouse genomic clone is shown. The *pfllox* vector is used as depicted to generate a *c-myb* targeting vector and contains two selectable markers *tk* and *neo* (black arrows). Thirty-four bp *loxP* sites are depicted as black arrowheads. (B) Homologous recombination between the wild-type (WT) *c-myb* allele in embryonic stem (ES) cells will generate the *c-myb*F[*tkneo*] allele to be used as a substrate for subsequent recombination by Cre recombinase. Positions of the probe used to determine homologous recombination and for additional genomic Southern blotting studies of targeted *c-myb* allele structure are depicted. (C) Production of ES cells bearing Type I and Type II deletions in the *c-myb*F[*tkneo*] allele will be generated following Cre expression and ganciclovir selection. Restriction enzyme sites: B, BamHI; E, EcoRI; H, HindIII; S, Sall; X, XhoI. Deletion of exon 6 results in the disruption of c-Myb DNA-binding domain, which renders the protein inactive.



of 11.5 kb, close to the wild-type band. To further confirm the deletions, DNA digested with BamHI was probed with *loxP* to identify two bands of sizes 6.0 kb and 2.5 kb (Type II) or a single band of size 11.5 kb (Type I).

We have microinjected the *c-myb*^F (Type II) ES cell clones into C57BL/6 blastocyst-stage embryos. To date several chimeric mice have been produced and are currently being used to generate heterozygous mice for the *c-myb*^F allele by crossing chimeric mice with C57/B6 mates. Germline transmission is being assessed by digesting tail DNA with BamHI and Southern blotting using the genomic probe to reveal two bands: 11.5 kb (wt) and 6.0 kb (recombinant). We plan to investigate deletion of *c-myb* gene in breast tissue using transgenic mice expressing Cre recombinase specifically in breast tissue. Dr. Lothar Hennighausen of NIH, under a collaborative agreement has agreed to provide us with two sets of transgenic mice, with the Cre recombinase under the control of Whey Acidic Protein (WAP) promoter and MMTV promoter. In these mice, the Cre recombinase is not expressed in any tissue other than the breast. Even in the breast tissue, the recombinase is not expressed in mammary tissue of virgin mice and the first expression of the recombinase was seen at day 14 of pregnancy and increased during lactation. Interestingly, the recombinase activity could be detected 30 days after weaning, suggesting that the transgene has been active in putative stem cells. These mice would be ideal to determine whether *c-myb* presence is necessary for breast epithelial cell proliferation during pregnancy and alveolar development and if the expression of this gene is necessary for ductal morphogenesis following involution.

To validate the results obtained from the mouse models in the human system, we have conducted parallel studies with human breast tumor cell lines. Analysis of several human breast tumor cell lines showed that the *c-myb* is expressed in a vast majority of ER+ human breast carcinoma cell lines, while *A-myb* expression is seen predominantly in ER- cell lines. To establish the role of *c-myb* in ER+ cell proliferation, we have constructed dominant negative mutants of c-Myb, which effectively block *c-myb*-mediated transactivation of target genes. Expression of these dominant negative mutants in ER+ breast tumor cell lines resulted in complete block to their proliferative potential. In addition, these tumor cell lines lost their tumorigenic activity as evidenced by their inability to grow in soft agar. These results firmly establish that *c-myb* gene plays an essential role in the proliferation of human breast carcinomas. We are currently in the process of assessing the role of *A-myb* in the proliferation of ER- breast carcinomas.